CervoMed says new AAIC analyses support 50 mg TID neflamapimod dose for planned DLB Phase 3 trial
CRVO•AAIC analyses support Phase 3 dosing plan
CervoMed presented AAIC 2026 analyses on neflamapimod in dementia with Lewy bodies, reframing Phase 2b results around Alzheimer’s co-pathology and drug exposure.
In the 159-patient RewinD-LB trial, exploratory data favored neflamapimod on CDR-SB in patients with plasma pTau181 <21 pg/mL.
Higher exposure in the extension (DP Batch B) showed 0.17 CDR-SB worsening versus 0.95 on placebo in the same patients (p=0.005).
MRI readouts showed slower right basal forebrain atrophy over 16 weeks, with volume stability through 48 weeks on continued treatment.
PK-PD work tied clinical and biomarker effects to ~4 ng/mL trough; 50 mg TID was selected for Phase 3, targeting ~90% above threshold.
